Immix Biopharma, Inc.
immixbio.comWhat Do They Do?
Develops cell therapies made from patients’ immune cells for AL amyloidosis and other serious diseases.
10-K for FY2025, filed Mar 25, 2026Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy…View ↗
NXC-201 is a next-generation CAR-T targeting B-cell maturation antigen (“BCMA”). CAR-T cell therapy is a type of immunotherapy that uses…View ↗
Our other programs include NXC-201 for treatment of select other serious diseases and other preclinical candidates.View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 25, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
−$11.6MView ↗
- ▲ +75% (Loss)
- vs −$6.6M in Q2 FY2025
From tissue-specific drugs to cell therapy
Earlier operations included tissue-specific drug development for solid tumors and inflammation alongside a cell-therapy program; the latest report centers on CAR-T for AL amyloidosis and other serious diseases.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 25, 2026Immix Biopharma, Inc. has the following two business units:View ↗
ImmixBio. ImmixBio is focused on developing Tissue Specific Therapeutics targeting solid tumors and immune-dysregulated diseases. As of…View ↗
We are a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics (“TSTx”)TM in oncology and…View ↗
Who Do They Compete With?
Competes with Abbvie, Caelum Biosciences, Alexion/AstraZeneca, and Janssen/Johnson & Johnson
10-K for FY2025, filed Mar 25, 2026We currently face and will continue to face competition for our development programs from groups that are developing therapies for oncology…View ↗
Loading...
